Banco Santander S.A. Has $27.89 Million Holdings in Pfizer Inc. (NYSE:PFE)

Key Points

• Banco Santander S.A. increased its stake in Pfizer Inc. by 8.7%, holding 1,100,506 shares valued at approximately $27.89 million as of its latest SEC filing.
• Pfizer's Q1 earnings report revealed earnings per share of $0.92, exceeding expectations, but revenue fell to $13.72 billion, below the forecast of $14.43 billion.
• The company declared a quarterly dividend of $0.43 per share, with a high dividend yield of 7.3%, despite a dividend payout ratio of 124.64%.

Banco Santander S.A. lifted its position in Pfizer Inc. (NYSE:PFE - Free Report) by 8.7% in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,100,506 shares of the biopharmaceutical company's stock after buying an additional 87,714 shares during the quarter. Banco Santander S.A.'s holdings in Pfizer were worth $27,887,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also made changes to their positions in the company. OVERSEA CHINESE BANKING Corp Ltd lifted its holdings in Pfizer by 65.9% during the 1st quarter. OVERSEA CHINESE BANKING Corp Ltd now owns 14,765 shares of the biopharmaceutical company's stock valued at $374,000 after purchasing an additional 5,865 shares during the last quarter. Privium Fund Management B.V. lifted its holdings in Pfizer by 47.1% during the 1st quarter. Privium Fund Management B.V. now owns 32,327 shares of the biopharmaceutical company's stock valued at $819,000 after purchasing an additional 10,349 shares during the last quarter. Jupiter Asset Management Ltd. lifted its holdings in Pfizer by 110.2% during the 1st quarter. Jupiter Asset Management Ltd. now owns 1,569,027 shares of the biopharmaceutical company's stock valued at $39,759,000 after purchasing an additional 822,518 shares during the last quarter. LSV Asset Management lifted its holdings in Pfizer by 10.2% during the 1st quarter. LSV Asset Management now owns 15,153,114 shares of the biopharmaceutical company's stock valued at $383,980,000 after purchasing an additional 1,400,622 shares during the last quarter. Finally, Mirabaud & Cie SA lifted its holdings in Pfizer by 9.9% during the 1st quarter. Mirabaud & Cie SA now owns 12,779 shares of the biopharmaceutical company's stock valued at $324,000 after purchasing an additional 1,150 shares during the last quarter. 68.36% of the stock is owned by institutional investors.

Pfizer Trading Up 5.0%

Shares of Pfizer stock traded up $1.19 on Tuesday, hitting $24.72. The stock had a trading volume of 79,693,977 shares, compared to its average volume of 45,694,074. The stock has a 50 day moving average of $24.37 and a 200 day moving average of $24.53. Pfizer Inc. has a twelve month low of $20.92 and a twelve month high of $30.43. The company has a debt-to-equity ratio of 0.64, a quick ratio of 0.96 and a current ratio of 1.26. The firm has a market capitalization of $140.51 billion, a P/E ratio of 17.95, a PEG ratio of 0.85 and a beta of 0.52.

Pfizer (NYSE:PFE - Get Free Report) last posted its quarterly earnings data on Tuesday, August 5th. The biopharmaceutical company reported $0.78 EPS for the quarter, topping analysts' consensus estimates of $0.57 by $0.21. The company had revenue of $14.65 billion for the quarter, compared to analyst estimates of $13.43 billion. Pfizer had a return on equity of 20.33% and a net margin of 12.62%. The firm's quarterly revenue was up 10.3% on a year-over-year basis. During the same period in the previous year, the firm earned $0.60 earnings per share. Sell-side analysts expect that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Pfizer Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, September 2nd. Shareholders of record on Friday, July 25th will be paid a $0.43 dividend. The ex-dividend date of this dividend is Friday, July 25th. This represents a $1.72 annualized dividend and a yield of 7.0%. Pfizer's payout ratio is 124.64%.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently weighed in on PFE shares. Leerink Partners dropped their target price on Pfizer from $28.00 to $26.00 and set a "market perform" rating for the company in a report on Wednesday, April 30th. HSBC dropped their target price on Pfizer from $27.00 to $26.00 and set a "buy" rating for the company in a report on Monday, May 19th. UBS Group lifted their target price on Pfizer from $24.00 to $25.00 and gave the stock a "neutral" rating in a report on Wednesday, April 30th. Berenberg Bank dropped their target price on Pfizer from $28.00 to $25.00 and set a "hold" rating for the company in a report on Thursday, May 29th. Finally, TD Cowen dropped their target price on Pfizer from $32.00 to $28.00 and set a "hold" rating for the company in a report on Tuesday, April 22nd. One analyst has rated the stock with a sell rating, eleven have issued a hold rating, six have given a buy rating and three have assigned a strong buy rating to the stock. Based on data from MarketBeat, the stock has an average rating of "Moderate Buy" and an average target price of $28.28.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.